A299660 Stock Overview
Develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cellid, Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,030.00 |
| 52 Week High | ₩17,310.00 |
| 52 Week Low | ₩1,733.00 |
| Beta | 1.42 |
| 1 Month Change | -17.94% |
| 3 Month Change | -13.72% |
| 1 Year Change | 12.53% |
| 3 Year Change | -89.76% |
| 5 Year Change | -81.94% |
| Change since IPO | -90.16% |
Recent News & Updates
Shareholder Returns
| A299660 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -8.5% | -2.3% | -1.9% |
| 1Y | 12.5% | 14.9% | -9.5% |
Return vs Industry: A299660 underperformed the KR Biotechs industry which returned 14.9% over the past year.
Return vs Market: A299660 exceeded the KR Market which returned -9.5% over the past year.
Price Volatility
| A299660 volatility | |
|---|---|
| A299660 Average Weekly Movement | 19.3% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A299660's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A299660's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Yuil Kang Chang | www.cellid.co.kr |
Cellid, Co., Ltd. develops immunotherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and sex organ cancer with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer with HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma with prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; BVAC-Neo.
Cellid, Co., Ltd. Fundamentals Summary
| A299660 fundamental statistics | |
|---|---|
| Market cap | ₩109.74b |
| Earnings (TTM) | -₩10.06b |
| Revenue (TTM) | ₩2.28b |
46.5x
P/S Ratio-10.6x
P/E RatioIs A299660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A299660 income statement (TTM) | |
|---|---|
| Revenue | ₩2.28b |
| Cost of Revenue | ₩1.87b |
| Gross Profit | ₩412.37m |
| Other Expenses | ₩10.47b |
| Earnings | -₩10.06b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -476.67 |
| Gross Margin | 18.06% |
| Net Profit Margin | -440.53% |
| Debt/Equity Ratio | 19.1% |
How did A299660 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 11:03 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cellid, Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|